United Bankshares, Inc. (UBSI) Trades at $34.35 After Triangle; Meridian Bioscience, Inc. (VIVO) Had 2 Bulls

Meridian Bioscience, Inc. (NASDAQ:VIVO) Logo

United Bankshares, Inc. (UBSI) formed triangle with $32.98 target or 4.00% below today’s $34.35 share price. United Bankshares, Inc. (UBSI) has $3.61 billion valuation. The stock increased 1.33% or $0.45 during the last trading session, reaching $34.35. About 438,508 shares traded. United Bankshares, Inc. (NASDAQ:UBSI) has declined 13.81% since May 5, 2017 and is downtrending. It has underperformed by 25.36% the S&P500.

Among 5 analysts covering Meridian Bioscience (NASDAQ:VIVO), 2 have Buy rating, 1 Sell and 2 Hold. Therefore 40% are positive. Meridian Bioscience had 13 analyst reports since July 28, 2015 according to SRatingsIntel. On Thursday, January 25 the stock rating was maintained by Canaccord Genuity with “Hold”. The company was upgraded on Monday, March 28 by Hilliard Lyons. The stock has “Hold” rating by Canaccord Genuity on Thursday, September 10. The rating was maintained by Robert W. Baird on Thursday, October 19 with “Hold”. The rating was maintained by Piper Jaffray with “Sell” on Thursday, July 27. The rating was maintained by Piper Jaffray with “Sell” on Thursday, September 21. The stock of Meridian Bioscience, Inc. (NASDAQ:VIVO) has “Sell” rating given on Thursday, January 25 by Piper Jaffray. The firm has “Hold” rating given on Thursday, January 25 by Robert W. Baird. The rating was downgraded by Hilliard Lyons to “Neutral” on Monday, March 21. The firm has “Sell” rating given on Thursday, October 19 by Piper Jaffray. See Meridian Bioscience, Inc. (NASDAQ:VIVO) latest ratings:

25/01/2018 Broker: Piper Jaffray Rating: Sell New Target: $11.0 Maintain
25/01/2018 Broker: Canaccord Genuity Rating: Hold New Target: $16.0 Maintain
25/01/2018 Broker: Robert W. Baird Rating: Hold New Target: $16.0 Maintain

Among 6 analysts covering United Bankshares Inc. (NASDAQ:UBSI), 0 have Buy rating, 0 Sell and 6 Hold. Therefore 0 are positive. United Bankshares Inc. had 14 analyst reports since August 4, 2015 according to SRatingsIntel. Boenning & Scattergood maintained United Bankshares, Inc. (NASDAQ:UBSI) on Tuesday, January 30 with “Hold” rating. Keefe Bruyette & Woods maintained it with “Hold” rating and $3800 target in Thursday, July 27 report. Boenning & Scattergood maintained the stock with “Hold” rating in Thursday, April 26 report. Sandler O’Neill maintained it with “Hold” rating and $38.0 target in Thursday, January 4 report. DA Davidson maintained it with “Neutral” rating and $38 target in Friday, April 27 report. The rating was maintained by Boenning & Scattergood with “Hold” on Thursday, July 27. As per Friday, November 3, the company rating was maintained by Keefe Bruyette & Woods. As per Thursday, December 21, the company rating was maintained by Keefe Bruyette & Woods. The rating was maintained by Keefe Bruyette & Woods with “Hold” on Thursday, June 1. The firm has “Market Perform” rating given on Monday, August 22 by Wood.

Since February 2, 2018, it had 0 insider purchases, and 3 sales for $4.41 million activity. Another trade for 69,020 shares valued at $2.56M was sold by CONVERSE PETER A. Another trade for 27,000 shares valued at $1.00 million was sold by Fitzgerald Michael P.

Investors sentiment decreased to 1.21 in Q4 2017. Its down 0.23, from 1.44 in 2017Q3. It dropped, as 16 investors sold United Bankshares, Inc. shares while 64 reduced holdings. 27 funds opened positions while 70 raised stakes. 69.78 million shares or 3.29% more from 67.55 million shares in 2017Q3 were reported. Delta Asset Mgmt Tn owns 200 shares for 0% of their portfolio. Rafferty Asset Mngmt Limited Com accumulated 5,894 shares. Thrivent Fin For Lutherans reported 22,903 shares. Invesco Ltd has 697,897 shares. Northern Trust invested in 0.03% or 2.90 million shares. Moreover, Virginia Retirement System Et Al has 0.02% invested in United Bankshares, Inc. (NASDAQ:UBSI). Stevens Cap Management Limited Partnership has 28,142 shares. Citadel Advisors Ltd Liability invested in 0.01% or 358,303 shares. City Hldgs Communications accumulated 18,616 shares or 0.2% of the stock. Great West Life Assurance Co Can invested in 63,460 shares or 0.01% of the stock. Natl Bank Of Ny Mellon, a New York-based fund reported 1.50 million shares. New York State Teachers Retirement Systems accumulated 0.01% or 110,897 shares. Bessemer Gp invested in 0% or 836 shares. California State Teachers Retirement Sys has 157,763 shares. Glenmede Trust Na accumulated 987 shares or 0% of the stock.

Meridian Bioscience, Inc., a life science company, develops, makes, distributes, and sells diagnostic test kits primarily for various gastrointestinal, viral, respiratory, and parasitic infectious diseases worldwide. The company has market cap of $592.31 million. The firm operates through Diagnostics and Life Science divisions. It has a 27.45 P/E ratio. The Diagnostics segment offers testing platforms and technologies, including isothermal DNA amplification under the illumigene brand; rapid immunoassays, a single-use immunoassays that can be used in point-of-care settings under the TRU, ImmunoCard, and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the Premier brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare brand.

The stock increased 0.90% or $0.12 during the last trading session, reaching $14. About 170,163 shares traded. Meridian Bioscience, Inc. (NASDAQ:VIVO) has risen 7.87% since May 5, 2017 and is uptrending. It has underperformed by 3.68% the S&P500.

Meridian Bioscience, Inc. (NASDAQ:VIVO) Institutional Positions Chart